Shigamab |
Monoclonal antibodies |
Stx-1, Stx-2 |
Escherichia coli |
Phase 2 clinical trial |
[8] |
Bezlotoxumab |
Monoclonal antibody |
Toxin B |
Clostridium difficile |
Completed phase 3 clinical trial |
[9, 10] |
MEDI4893 |
Monoclonal antibody |
α-hemolysin |
Staphylococcus aureus |
Phase 2 clinical trial |
[11] |
Compounds 1–9 |
Small molecule |
Type 2 secretion |
Pseudomonas aeruginosa, Burkholderia pseudomallei |
Preclinical (inhibition of bacterial secretion |
[12] |
Compounds 7086, 7832, 7812 |
Small molecules |
Type 3 secretion |
Yersinia pestis |
Preclinical (efficacy in cell culture) |
[13] |
Salicylidene acylhydrazides |
Small molecules |
Type 3 secretion |
Salmonella, Shigella, Chlamydia, Yersinia, Pseudomonas spp |
Preclinical (efficacy in mice) |
[14] |
CHIR-1 |
Small molecule |
Type 4 secretion |
Helicobacter pylori |
Preclinical (efficacy in mice) |
[15] |